BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:RYZ801 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of RYZ801\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06726161-11185@assetmemo.bio
DTSTAMP:20261121T005614Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:RYZ801: Phase 1/2 readout est. (NCT06726161)
DESCRIPTION:RYZ801\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Study of
  the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Iden
 tify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC\nEstimate
 d primary completion: June 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ryz801#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06726161
URL:https://assetmemo.bio/drug/ryz801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
